Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies

Table 1

EGFR targeted agents.

Agent	Class	Indication	Dose
Erlotinib	TKI	-Locally advanced or metastatic NSCLC after at least one prior chemotherapy regimen	100–150 mg/day cancer
		-Locally advanced or metastatic pancreatic cancer in combination with gemcitabine
Gefitinib	TKI	- As single agent Locally advanced or metastatic NSCLC after at least platinum based and docetaxel chemotherapy regimen (only in the USA)	250 mg/day
Catuximab	mAb	- Locally or regionally advanced squamous cell carcinoma of head and neck in combination with radiotherapy	400 mg/m^2 initial dose followed by 250 mg/m^2 weekly
		- As single agent for recurrent or metastatic squamous cell carcinoma of head and neck after failure of platinum-based chemotherapy
		- As single agent in EGFR-expressing metastatic colorectal carcinoma in case of intolerance to irinotecan-based chemotherapy
		- In combination with irinotecan in EGFR-expressing metastatic colorectal carcinoma in patients refractory to irinotecan-based chemotherapy
Panitumumab	mAb	- In EGFR-expressing metastatic colorectal carcinoma in patients in progression on or following fliuoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy	6 mg/kg iv every 14 days
Bevacizumab	mAb	- Advanced colorectal cancer patients receiving first- and second-line intravenous 5-FU-based chemotherapy for the treatment	5–15 mg/kg/2 weeks
		- In combination with carboplatin and paclitaxel, for first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic nonsquamous, nonsmall cell lung cancer
		- In combination with paclitaxel for the treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer.